Iovance Biotherapeutics will build a new facility in Philadelphia that will house the commercial and clinical production of autologous TIL products, including drug candidate lifileucel. The company intends to invest about $75 million for the site.
Iovance expands production facility in Philadelphia
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.